Evolutionary origin of the type 2 corticotropin-releasing hormone receptor γ splice variant

被引:1
|
作者
De Groef, Bert [1 ]
Wawrzyczek, Stanislaw K. [1 ]
Watanabe, Yugo [1 ]
Noy, Ellyse B. [1 ]
Reser, David H. [2 ]
Grommen, Sylvia V. H. [1 ]
机构
[1] La Trobe Univ, Dept Physiol Anat & Microbiol, Bundoora, Vic, Australia
[2] Monash Univ, Dept Physiol, Clayton, Vic, Australia
关键词
corticotropin-releasing hormone receptor; exaptation; exonization; gene evolution; primates; splice variants; transposable elements; FACTOR CRF RECEPTOR; EXONS; IDENTIFICATION; MECHANISMS;
D O I
10.1111/gtc.12673
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Many G protein-coupled receptors have splice variants, with potentially different pharmaceutical properties, expression patterns and roles. The human brain expresses three functional splice variants of the type 2 corticotropin-releasing hormone: CRHR2 alpha, -beta and -gamma. CRHR2 gamma has only been reported in humans, but its phylogenetic distribution, and how and when during mammalian evolution it arose, is unknown. Based on genomic sequence analyses, we predict that a functional CRHR2 gamma is present in all Old World monkeys and apes, and is unique to these species. CRHR2 gamma arose by exaptation of an intronic sequence-already present in the common ancestor of primates and rodents-after retrotransposition of a short interspersed nuclear element (SINE) and mutations that created a 5 ' donor splice site and in-frame start codon, 32-43 million years ago. The SINE is not part of the coding sequence, only of the 5 ' untranslated region and may therefore play a role in translational regulation. Putative regulatory elements and an alternative transcriptional start site were added earlier to this genomic locus by a DNA transposon. The evolutionary history of CRHR2 gamma confirms some of the earlier reported principles behind the "birth" of alternative exons. The functional significance of CRHR2 gamma, particularly in the brain, remains to be showed.
引用
收藏
页码:318 / 323
页数:6
相关论文
共 50 条
  • [21] A corticotropin-releasing hormone type I receptor antagonist delays parturition in sheep
    Chan, EC
    Falconer, J
    Madsen, G
    Rice, KC
    Webster, EL
    Chrousos, GP
    Smith, R
    ENDOCRINOLOGY, 1998, 139 (07) : 3357 - 3360
  • [22] Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety
    Skutella, T
    Probst, JC
    Renner, U
    Holsboer, F
    Behl, C
    NEUROSCIENCE, 1998, 85 (03) : 795 - 805
  • [23] Molecular analysis of the corticotropin-releasing hormone receptor type 2 gene fragment in anorexia nervosa
    Karlik, Alicja
    Korman, Eugeniusz
    Maceluch, Jaroslaw
    Niedziela, Marek
    PSYCHIATRIA POLSKA, 2008, 42 (02) : 209 - 218
  • [24] Corticotropin-releasing hormone and corticotropin-releasing hormone receptor 1 mediate acute stress-induced prefrontal cortex dysfunctions
    Uribe-Marino, A.
    Solfrank, B.
    Balsevich, G.
    Santarelli, S.
    Massana, M.
    Harbich, D.
    Mueller, M. B.
    Schmidt, M. V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S368 - S368
  • [25] Corticotropin-releasing hormone physiology
    Majzoub, Joseph A.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2006, 155 : S71 - S76
  • [26] Corticotropin-releasing hormone receptors
    Hillhouse, EW
    Randeva, H
    Ladds, G
    Grammatopoulos, D
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2002, 30 : 428 - 432
  • [27] RADIOIMMUNOASSAY OF CORTICOTROPIN-RELEASING HORMONE
    RUCKERT, Y
    ROHDE, W
    FURKERT, J
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY, 1990, 96 (02): : 129 - 137
  • [28] CORTICOTROPIN-RELEASING HORMONE IN HUMANS
    ORTH, DN
    ENDOCRINE REVIEWS, 1992, 13 (02) : 164 - 191
  • [29] Reproductive corticotropin-releasing hormone
    Vitoratos, Nikolaos
    Papatheodorou, Dimitrios C.
    Kalantaridou, Sophia N.
    Mastorakos, George
    WOMEN'S HEALTH AND DISEASE: GYNECOLOGIC, ENDOCRINE, AND REPRODUCTIVE ISSUES, 2006, 1092 : 310 - 318
  • [30] Corticotropin-releasing hormone and inflammation
    Webster, EL
    Torpy, DJ
    Elenkov, IJ
    Chrousos, GP
    NEUROIMMUNOMODULATION: MOLECULAR ASPECTS, INTEGRATIVE SYSTEMS, AND CLINICAL ADVANCES, 1998, 840 : 21 - 32